Riding the Revolution in Prostate Cancer Diagnosis & Treatment

Tomer Schatzberger

Chief Executive Officer

UC-CARE USA, Inc.

Confidential

The Problem Untargeted biopsies

1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581822/

Miss nearly 40% of men with moderate/high grade disease (Gleason 7+)1

Patients move during biopsies due to discomfort - can lead to poor accuracy of biopsies

Increased risk of

• Repeat biopsies (~ 50%)

• Infection

• Delayed treatment C

C

CBlind 12-core needle biopsy

C

= Prostate Biopsy

B

B B

B

B

B

B

B

B

B

BB

= Cancer

B

Bladder

The ProblemBiopsy processing deficiencies

Up to 40% of tissue never analyzed2 due to • Fragmentation

• Tangling of cores

• Lost tissue during processing

Cannot identify exact cancer location within specimen leading to

• Unnecessary whole prostate treatment cost and complications

• Incontinence (diapers) and/or Impotence

Extremely high lab processing cost to put each specimen in individual jars

• One specimen/jar will still have inferior performance

2 2015 American Urology Association Conference Presentation

Prostate Cancer Market

1 in 6 men US annual statistics

1.5MBiopsy

procedures

175KMen diagnosed with prostate

cancer

32KMen

will die

Navigo MRI-Ultrasound Fusion System

• Fuses ultrasound (US) to MRI image for better targeting

• Targeted biopsies are 2-3X more sensitive for prostate cancer

• Insensitive to patient movement

• Provides biopsy & treatment guidance

SmartBxDisposable Cassette

• Safeguards specimen

• Pinpoints exact cancer location for treatment

• Saves lab time & cost

• Can be used with any fusion system

FDA-ClearedSolutions

SmartBx Disposable Cassette Opportunity for all soft tissue biopsies

Peer-Reviewed SmartBx DataBMC Urology (2019 19-23)

• 31% increase in detection of clinically significant high grade disease

• 30% increase in biopsy core length

• 95% reduction in biopsy fragmentation

Up to 50% lab cost savings

• 2 specimens processed at a time per cassette with less handling

SmartBx Standard Biopsy

Navigo Competitive AdvantagesOnly fusion system meeting needs of major medical centers as well as community sites

• Accurate. Real-time 3D biopsy localization & movement compensation; SmartBx

• Automated. Single person operation; automatic biopsy marking

• Affordable. Equipment, software, service, financing

Cancer

Targeted

Patients

• Want high detection• Want less invasive

treatment options• Avoid diapers and impotence

Pathologists

SmartBx• Improves biopsy quality > 25%

cancer detection + exact location • Reduces processing costs • Gains biopsy referrals

Navigo Fusion + SmartBx• Improves cancer detection• SmartBx unique localization enables

focal treatment/active surveillance • Attracts new patients

Urologists

Customer Triad

Traction: USA Users, Partners and PilotsAlready used in at least 13 U.S. states and multiple countries

SmartBx Global Annual Recurring Revenue •Prostate: $450M •Breast: $810M •All Soft Tissue: $2.7B

Fusion + MRI Software + Service : $1.5B+

Sources

Urology business development manager with BK Ultrasound

https://sperlingprostatecenter.com/mritrus-fusion-biopsies/

https://www.sec.gov/Archives/edgar/data/859737/000119312507145827/d425.htm

Patent Protection USA, Canada, Europe, Japan, China

Navigo and SmartBx Market Opportunity Summary

Navigo

• Proven Fusion need - ~400 units in leading US medical centers

- Only ~15% of market

• Community sites (~85%) face losing biopsy procedures > need Fusion

• Navigo offering ROI plus market-leading performance- Compatible with most available US

- Movement compensation, essential for

clinics

- Automation, one operator

SmartBx• For the Urologist

- Best localization- 25% detection improvement

• For the Path Lab- Can offer highest performance to Urologist

- Substantial cost reduction

• Compatible with any Fusion system (including the 400 installed units)

• No competition

Financials – 5 Year Plan

0

20

40

60

80

100

120

2019 2020 2021 2022 2023

Rev

enu

e in

Mill

ion

s

Recurring Disposable Capital

Q1 2021Breakeven

1.5

54.9

23.7

7.1

102.7

Leadership

Founder, Chairman & CEO

Shaike Schatzberger.

Chief Executive Officer

Tomer Schatzberger

Board Members

Prof. Yoram PaltiItzhak Shenberg, PhD

Director of U.S. Strategy

Kim StebbingsVP and COO

Galit Natan

UC-CARE Israel UC-CARE USA

The Ask

• Raising $10M including $3.5M CLA converted

• Use of Proceeds

• Grow USA Sales & Marketing

• R&D/Product: SmartBx for breast

• Mfg: Increase gross margins (90%)

Summary

• Very big market

• Revolution in prostate cancer treatment driving change

• Unique superior solution (Technology, Patents)

• Experienced team

• Winning business model

Tomer SchatzbergerCEO, UC-CARE, USA

tomers@uc-care.com

UC-CARE Medical Systems Ltd. Yokneam, Israel and Tampa, FL

(813) 413-7147

www.uc-care.com